ReviewMediastinum (Hong Kong, China)2025
Immune aberrations in thymic epithelial tumors.
Review in Mediastinum (Hong Kong, China), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immune checkpoint inhibitors in thymic epithelial tumors: current evidence, immune-related toxicity, and perioperative considerations-a narrative review.Journal of thoracic disease · 2026Review
- Integrated spatial transcriptomics and pan-cancer XGBoost modeling uncover spatial drivers of immune exclusion and predict immunotherapy response.Cancer immunology, immunotherapy : CII · 2026Article
- Systemic therapy for advanced thymic epithelial tumors: a narrative review of current evidence and perspectives.Mediastinum (Hong Kong, China) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymic epithelial tumors (TETs) are rare cancers that arise from cortical or medullary thymic epithelial cells and are associated with unique clinical, genomic and immunological features that include a poorly understood predisposition towards autoimmunity. The risk for autoimmune disease can be traced back to the physiological role of the thymus in T cell development. Recent studies have revealed key differences in the immune cell composition and tumor immune microenvironment of thymomas and thymic carcinomas (TCs). Thymomas contain a greater proportion of immature double positive T cells whereas TCs have larger numbers of differentiated single positive T cells. The proportion of B cells, dendritic cells, macrophages and regulatory T cells vary depending on TET histology. Thymomas exhibit higher immune cell infiltration whereas TCs are characterized by a pronounced stromal signature. Histology-based differences in T cell receptor diversity and in the cytokine profile of the tumor microenvironment have also been described. Programmed cell death-ligand 1 expression is variable in TETs and confounded by physiological expression in the normal thymus. Knowledge of the immune cell composition and the tumor immune microenvironment of TETs is essential to understand the risks of paraneoplastic autoimmunity and treatment-related toxicity in the era of immunotherapy. This review synthesizes recent advances in thymic biology and tumor immunology to frame the immune landscape of TETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.